Literature DB >> 17690614

Surgical management of jugular foramen meningiomas: a series of 13 cases and review of the literature.

Mario Sanna1, Andrea Bacciu, Maurizio Falcioni, Abdelkader Taibah, Paolo Piazza.   

Abstract

OBJECTIVE: Primary meningiomas occurring within the jugular foramen are exceedingly rare lesions presumed to originate from arachnoid-lining cells situated within the jugular foramen. The objective of this study is to analyze the management and outcome in a series of 13 primary jugular foramen meningiomas collected at a single center. STUDY
DESIGN: Retrospective study.
SETTING: Quaternary referral otology and skull base private center.
METHODS: Charts belonging to 13 consecutive patients with pathologically confirmed jugular foramen meningioma surgically treated between September 1991 and May 2005 were examined retrospectively. The follow-up of the series ranged from 12 to 120 (mean, 42.8 +/- 27.5) months.
RESULTS: Four (28.5%) patients underwent single-stage tumor removal through the petro-occipital transigmoid (POTS) approach. In two patients with preoperative unserviceable hearing, a combined POTS-translabyrinthine approach was adopted. Two patients underwent a combined POTS-transotic approach because of massive erosion of the carotid canal. A modified transcochlear approach type D with posterior rerouting of the facial nerve and transection of the sigmoid sinus and jugular bulb was performed in two patients with a huge cerebellopontine angle tumor component with extension to the prepontine cistern together with massive involvement of the petrous bone and middle ear and encasement of the vertical and horizontal segments of the intrapetrous carotid artery. In one patient with evidence of a dominant sinus on the site of the tumor, a subtotal tumor removal via an enlarged translabyrinthine approach (ETLA) was planned to resect the intradural component of the tumor. Two patients in our series underwent a planned staged procedure on account of a huge tumor component in the neck. One of these patients underwent a first-stage infratemporal fossa approach type A to remove the tumor component in the neck; the second-stage intradural removal of the tumor was accomplished via an ETLA. The last patient underwent a first-stage modified transcochlear type D approach to remove the intradural tumor component followed by a second-stage transcervical procedure for removal of the extracranial component. Gross total tumor removal (Simpson grade I-II) was achieved in 11 (84.6%) cases. Subtotal removal of the tumor was accomplished in two patients. Good facial nerve function (grades I and II) was achieved in 46.1% of cases, whereas acceptable function (grade III) was achieved in the remaining cases 1 year after tumor removal. Hearing was preserved at the preoperative level in all four patients who underwent surgery via the POTS approach. After surgery, no patient recovered function of the preoperatively paralyzed lower cranial nerves. A new deficit of one or more of the lower cranial nerves was recorded in 61.5% of cases.
CONCLUSIONS: Surgical resection is the treatment of choice for jugular foramen meningiomas. Among the various surgical techniques proposed for dealing with these lesions, we prefer the POTS approach alone or combined with the translabyrinthine or transotic approaches. Despite the advances in skull base surgery, new postoperative lower cranial nerve deficits still represent a challenge.

Entities:  

Mesh:

Year:  2007        PMID: 17690614     DOI: 10.1097/MLG.0b013e3180cc20a3

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  15 in total

1.  [A young patient with paraganglioma syndrome type I. An interdisciplinary challenge].

Authors:  C Brase; H Neumann; M Lell; S Schwarz-Furlan; K Rogler; J Hornung
Journal:  HNO       Date:  2012-08       Impact factor: 1.284

Review 2.  Contemporary surgical outcome for skull base meningiomas.

Authors:  Chien-Min Chen; Abel Po-Hao Huang; Lu-Ting Kuo; Yong-Kwang Tu
Journal:  Neurosurg Rev       Date:  2011-05-26       Impact factor: 3.042

3.  WHO grade I meningiomas: classification-tree for prognostic factors of survival.

Authors:  Jean-Michel Lemée; Holger Joswig; Michele Da Broi; Marco Vincenzo Corniola; David Scheie; Karl Schaller; Eirik Helseth; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2019-06-10       Impact factor: 3.042

4.  Function-Preserving Multimodal Treatment for Jugular Foramen Meningiomas.

Authors:  Seiro Ito; Takashi Saegusa; Yoshinori Ozawa; Yoshinori Higuchi; Yasuo Iwadate; Toru Serizawa; Osamu Nagano; Yusuke Kageyama; Iwao Yamakami
Journal:  J Neurol Surg B Skull Base       Date:  2018-08-21

5.  Comparative results of infratemporal fossa approach with or without facial nerve rerouting in jugular fossa tumors.

Authors:  J L Llorente; S Obeso; F López; J C Rial; A Coca; C Suárez
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-24       Impact factor: 2.503

6.  Vagoglossopharyngeal-associated syncope due to a retained bullet in the jugular foramen.

Authors:  Michael J Link; Colin L W Driscoll; Yoshua Esquenazi
Journal:  Skull Base       Date:  2010-03

7.  Paragangliomas of head and neck: a treatment option with CyberKnife radiosurgery.

Authors:  Livia C Bianchi; Marcello Marchetti; Lorenzo Brait; Achille Bergantin; Ida Milanesi; Giovanni Broggi; Laura Fariselli
Journal:  Neurol Sci       Date:  2009-09-23       Impact factor: 3.307

8.  Microsurgical management of primary jugular foramen meningiomas: a series of 22 cases and review of the literature.

Authors:  Jie Tang; Liwei Zhang; Junting Zhang; Zhen Wu; Xinru Xiao; Dabiao Zhou; Guijun Jia; Wang Jia
Journal:  Neurosurg Rev       Date:  2016-06-23       Impact factor: 3.042

9.  Radiation-induced intratumoral necrosis and peritumoral edema after gamma knife radiosurgery for intracranial meningiomas.

Authors:  Sang Ryul Lee; Kyung Ah Yang; Sung Kyu Kim; Se-Hyuk Kim
Journal:  J Korean Neurosurg Soc       Date:  2012-08-31

10.  Long-Term Results of Gamma Knife Radiosurgery for Intracranial Meningioma.

Authors:  Chang Ki Jang; Hyun Ho Jung; Jong Hee Chang; Jin Woo Chang; Yong Gou Park; Won Seok Chang
Journal:  Brain Tumor Res Treat       Date:  2015-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.